TinkerTx’s FORGE™ platform chemically fuses multiple RNA strands into a single, stable oligonucleotide that can simultaneously modulate several validated targets in the brain. This multi‑target approach enables coordinated pathway regulation for polygenic neurological disorders such as Alzheimer’s disease and Dravet syndrome, reducing dosing complexity and manufacturing overhead compared to separate monogenic agents.
Funding
Funding not disclosed
Founders
Product
Problem
Current RNA therapeutics such as siRNA and antisense oligonucleotides target a single gene, which limits their effectiveness for polygenic neurological disorders that involve multiple dysregulated pathways. This monogenic focus often requires combination therapies, increasing dosing complexity and the risk of adverse effects.
Solution
TinkerTx’s FORGE™ platform generates chemically optimized fused oligonucleotides that can simultaneously modulate several validated disease targets within one construct. By linking multiple active sequences, the platform enables coordinated regulation of distinct molecular pathways implicated in complex brain diseases. The multi‑target design aims to enhance therapeutic efficacy while reducing the number of administrations needed compared with separate monogenic agents. TinkerTx applies this approach to indications such as Alzheimer’s disease and Dravet syndrome, where simultaneous pathway engagement is expected to improve clinical outcomes.
Target Audience
Primary customers are pharmaceutical and biotech companies developing treatments for polygenic neurological disorders, as well as academic research groups seeking multi‑target RNA therapeutic platforms.
Features
- Proprietary FORGE™ technology that chemically fuses multiple RNA strands into a single, stable therapeutic molecule
- Optimized chemistry to preserve potency, nuclease resistance, and brain penetrance of each target‑specific component
- Ability to address up to several validated targets per construct, enabling polygenic disease modulation
- Streamlined manufacturing workflow that produces a single multi‑target product rather than multiple separate oligonucleotides
- Preclinical validation pipeline focused on complex neurological indications, including Alzheimer’s disease and Dravet syndrome